Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines

被引：1
|
作者：
Escudier, Bernard [1 ]
Joly, Florence [2 ]
Soria, Jean-Charles [3 ]
机构：
[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
[2] Ctr Francois Baclesse, F-14076 Caen 05, France
[3] Inst Gustave Roussy, SITEP, F-94805 Villejuif, France
来源：
BULLETIN DU CANCER | 2011年 / 98卷
关键词：
renal cell carcinoma; immunotherapy; nephrectomy; anti-angiogenesis; mammalian target of rapamycin; guidelines; toxicities; CELL CARCINOMA; INTERFERON-ALPHA; DOUBLE-BLIND; TEMSIROLIMUS; SUNITINIB;
D O I：
10.1684/bdc.2011.1444
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Advanced renal cell carcinoma (RCC) is associated with a poor prognosis and is refractory to standard chemotherapy. Recent progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The management of metastatic RCC has been revolutionized with the development of targeted molecular therapies against VEGF-VEGFR and mTOR. Randomized phase III clinical trials demonstrated clinical benefit for patients with advanced RCC in overall survival and progression free survival. Guidelines for the management of side effects induced by these targeted therapies seem to be warranted. Delta
引用
收藏
页码：S3 / S6
页数：4
相关论文
共 50 条
  • [1] Selected Toxicities of Targeted Therapies: Presentation and Management
    Kollmannsberger, Christian
    Mitchell, Teresa
    SEMINARS IN ONCOLOGY, 2013, 40 (04) : 499 - 510
  • [2] Management of side-effects of targeted therapies in renal cancer: cardiovascular side-effects
    Ederhy, Stephane
    Duclos, Brigitte
    Mahammedi, Hakim
    Doublet, Jean-Dominique
    BULLETIN DU CANCER, 2011, 98 : S19 - S34
  • [3] Targeted therapies in metastatic renal cancer in 2009
    Bastien, Laurence
    Culine, Stephane
    Paule, Bernard
    Ledbai, Souhil
    Patard, Jean Jacques
    de la Taille, Alexandre
    BJU INTERNATIONAL, 2009, 103 (10) : 1334 - 1342
  • [4] Renal cell carcinoma management and therapies in 2010
    Albouy, B.
    Goupil, M. Gross
    Escudier, B.
    Massard, C.
    BULLETIN DU CANCER, 2010, 97 : S17 - S28
  • [5] Management of side-effects of targeted therapies in renal cancer: gastrointestinal side-effects
    Davin, Jean-Louis
    Ducrotte, Philippe
    Houede, Nadine
    BULLETIN DU CANCER, 2011, 98 : S69 - S78
  • [6] Management of side effects of targeted therapies in renal cancer: iatrogenic side effects
    Massard, Christophe
    Patard, Jean-Jacques
    Hermine, Olivier
    Ravaud, Alain
    BULLETIN DU CANCER, 2011, 98 : S79 - S94
  • [7] Toxicities of Targeted Therapy and Their Management in Kidney Cancer
    Di Lorenzo, Giuseppe
    Porta, Camillo
    Bellmunt, Joaquim
    Sternberg, Cora
    Kirkali, Ziya
    Staehler, Michael
    Joniau, Steven
    Montorsi, Francesco
    Buonerba, Carlo
    EUROPEAN UROLOGY, 2011, 59 (04) : 526 - 540
  • [8] Management of side effects of targeted therapies in renal cancer: stomatological side effects (mucositis, epistaxis)
    Agbo-Godeau, Scarlette
    Nicolas-Virelizier, Emmanuelle
    Scotte, Florian
    BULLETIN DU CANCER, 2011, 98 : S117 - S126
  • [9] Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma
    Anh Pham
    Ye, Da-Wei
    Pal, Sumanta
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (12) : 517 - 527
  • [10] A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma
    Alasker, Ahmed
    Meskawi, Malek
    Sun, Maxine
    Ismail, Salima
    Hanna, Nawar
    Hansen, Jens
    Tian, Zhe
    Bianchi, Marco
    Perrotte, Paul
    Karakiewicz, Pierre I.
    CANCER TREATMENT REVIEWS, 2013, 39 (04) : 388 - 401
12345